Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
287615 containing HBsAg with adjuvants · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| 287615 containing HBsAg with adjuvants | BIOLOGICAL | - |
Inclusion Criteria: * Healthy volunteers between 18 and 40 years of age * Written informed consent obtained from subject * Female of non-childbearing potential Exclusion Criteria: * Any hepatitis B vaccination. * Positive HBV serological markers: anti-HBs, anti-HBc, and/ or HBsAg * Pregnancy or l...
287615 is an investigational vaccine being studied for the prevention of Hepatitis B Disease. It is a candidate adjuvanted vaccine developed by GSK plc. The vaccine is currently in Phase 1 clinical development, meaning it is still being tested in clinical trials and is not yet approved for public use.
287615 is being developed by GSK plc, a global biopharma company listed on the stock exchange under the ticker GSK. The company conducted a Phase 1 clinical trial to evaluate the safety and efficacy of this candidate adjuvanted vaccine for Hepatitis B Disease.
287615 is in Phase 1 clinical development. It is an investigational vaccine for Hepatitis B Disease and has not been approved by regulatory authorities. The Phase 1 trial has been completed, and the vaccine remains in early-stage clinical testing.
287615 has been studied in one completed Phase 1 clinical trial with the identifier NCT00508833. This trial, titled 'Safety and Efficacy of SmithKline Beecham (GlaxoSmithKline [GSK]) Biologicals' Candidate Adjuvanted Vaccines (287615)', enrolled 200 participants in Belgium to evaluate the vaccine's safety and efficacy for Hepatitis B Disease.
No, 287615 is not a monoclonal antibody. It is a vaccine that contains HBsAg with adjuvants, designed to elicit an immune response against Hepatitis B. The vaccine is being developed by GSK plc and is currently in Phase 1 clinical trials for the prevention of Hepatitis B Disease.